Interleukin‐2 Receptor Levels in the Sera of Rheumatoid Arthritis Patients Treated with Methotrexate
Open Access
- 1 January 1994
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 37 (1) , 50-56
Abstract
Objective. To evaluate the association of the level of soluble serum interleukin-2 receptor (sIL-2R) with disease activity and response to therapy in patients with rheumatoid arthritis (RA). Methods. The sIL-2R levels of 148 patients with refractory RA were determined by enzyme-linked immunosorbent assay. This parameter was correlated with other clinical observations obtained during a prospective, randomized, placebo-controlled trial of methotrexate, sponsored by the Cooperative Systematic Studies of Rheumatic Diseases consortium. Using statistical modeling, the usefulness of sIL-2R as a measure of disease activity and a predictor of outcome was evaluated. Results. The mean sIL-2R level in all RA patients was markedly elevated compared with that in normal control subjects, and decreased significantly during the trial. There was no correlation of the sIL-2R level and the joint pain/tenderness count either at study entry or study end. There was a significant correlation of the sIL-2R level and the erythrocyte sedimentation rate, both at study entry and study end. A multiple linear regression model showed that treatment with methotrexate, but not the sIL-2R level or the change in sIL-2R level, predicted a change in joint count. A stepwise multiple logistic regression model defined no significant predictive information for outcome for the level of sIL-2R at study entry. Conclusion. After controlling for the simultaneous effects of other important clinical variables, the level of sIL-2R does not appear to predict the response to methotrexate in patients with refractory RA. Further analysis of cohorts of patients with earlier RA needs to be performed.Keywords
This publication has 20 references indexed in Scilit:
- Soluble immunologic products in scleroderma seraClinical Immunology and Immunopathology, 1991
- Mechanisms of Immune Injury in Rheumatoid Arthritis: Evidence for the Involvement of T Cells and Heat‐Shock ProteinImmunological Reviews, 1990
- Serum interleukin-2 receptor responses to immunizationClinical Immunology and Immunopathology, 1990
- Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritisClinical Immunology and Immunopathology, 1990
- Soluble and cellular markers of immune activation in patients with systemic sclerosisClinical Immunology and Immunopathology, 1990
- Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseasesClinical Immunology and Immunopathology, 1989
- Serum levels of interleukin‐2 receptor and activity of rheumatic diseases characterized by immune system activationArthritis & Rheumatism, 1988
- Serum interleukin-2-receptor in rheumatoid arthritis: A prognostic indicator of disease activity?Journal of Autoimmunity, 1988
- Elevated soluble interleukin‐2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritisArthritis & Rheumatism, 1988
- Expression of interleukin 2 receptors on activated human B cells.Journal of Experimental Medicine, 1984